Evaluating the economic benefits of traffic optimization from connected and autonomous vehicles (CAVs) and relevant traffic organization methods is significant, which will help to put forward suggestions for policymakers to promote the application of CAVs. The impacts and related benefits from CAVs with level 2 automation (L2 CAVs) on traffic efficiency and energy consumption of expressways are analyzed in this paper. Average travel time and actual road capacity are on behalf of traffic efficiency while average electric energy consumption is used to compute traffic energy consumption. The corresponding traffic economic benefits consist of travel-time-saving benefits, road construction benefits, and energy-saving benefits. A benefit evaluation framework is newly proposed and microscopic traffic simulation software is applied as the experiment platform. Different market penetration rates of L2 CAVs and various traffic flow statuses are considered. Besides, dedicated lanes for CAVs are also involved in this research, which are regarded as a traffic organization method expected to promote the realization of CAV’s traffic benefits. It is found that L2 CAVs can save the average travel time and reduce average energy consumption for a single vehicle in most scenes. However, negative impacts on energy consumption are observed in several scenes due to the increase of actual road capacity. Positive economic benefits are obtained as soon as the traffic flow rate is out of saturation, which become increasingly higher as CAV’s market penetration rate turns larger. Additionally, amplification in traffic economic benefits appears only if CAV lanes are provided under proper conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.